Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $133
Blueprint Medicines Analyst Ratings
Wolfe Research Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $132
Morgan Stanley Assumes Blueprint Medicines at Equal-Weight, Lowers Price Target of $100
Blueprint Medicines Analyst Ratings
Morgan Stanley Initiates Blueprint Medicines(BPMC.US) With Hold Rating, Announces Target Price $100
Piper Sandler Initiates Blueprint Medicines(BPMC.US) With Hold Rating, Announces Target Price $119
Wolfe Research Initiates Blueprint Medicines(BPMC.US) With Buy Rating, Announces Target Price $132
Blueprint Medicines Price Target Announced at $135.00/Share by Jefferies
Jefferies Initiates Blueprint Medicines(BPMC.US) With Buy Rating, Announces Target Price $135
Scotiabank Initiates Coverage On Blueprint Medicines With Sector Outperform Rating, Announces Price Target of $150
Leerink Partners Upgrades Blueprint Medicines(BPMC.US) to Hold Rating
Blueprint Medicines: Hold Rating Amid Concerns Over Ayvakit's Liver Function Test Elevations
Blueprint Medicines Price Target Maintained With a $125.00/Share by Citizens Capital Markets
Blueprint Medicines Analyst Ratings
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Cuts Target Price to $125
Stifel Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $155
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
JMP Securities Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Raises Target Price to $126
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105